Tyloxapol

Summary

Tyloxapol (CHEMBL1201548) is an approved unknown (ATC R05CA01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: R05CA01
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201548
Name	Tyloxapol
Type	Unknown
Max phase	4
ATC	R05CA01

Also known as: Alevaire, NSC-90255, Superinone, Tacholiquine, Tiloxapol, Tyloxapol, Tyloxapol component of exosurf neonatal, TYLOXAPOL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02515799	PHASE4	COMPLETED	Mucolytic Effectiveness of Tacholiquine ® in Chronic Bronchitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).